Combined leadless pacing and subcutaneous defibrillation strategy in a high-risk patient: first case report from Peru

• Autores: Vallejos-Barrientos, Alexis, Davila-Flores, Diego, Soto-Becerra, Richard, Cabrera-Saldaña, Mario, Guevara-Caicedo, Carolina, Gonzales-Luna, Ana Cecilia, Cueva-Parra, Ángel, Payano-Rojas, Marisel, Zelaya-Castro, Pío
• Formato: artículo
• Fecha de Publicación: 2025
• Institución: Seguro Social de Salud
• Repositorio: ESSALUD-Institucional
• Lenguaje: inglés
• OAI Identifier: oai:repositorio.essalud.gob.pe:20.500.12959/5987
• Enlace del recurso: https://hdl.handle.net/20.500.12959/5987; https://doi.org/10.47487/apcyccv.v6i4.513
• Nivel de acceso: acceso abierto
• Materia: Pacemaker; Artificial; Defibrillators; Heart Failure; Infection; Marcapaso Artificial; Desfibriladores Implantables; Insuficiencia Cardíaca; Infecciones; https://purl.org/pe-repo/ocde/ford#3.02.04

We present the case of a 51-year-old male with non-ischemic dilated cardiomyopathy and complete atrioventricular block, who was previously implanted with a cardiac resynchronization therapy defibrillator. The patient developed signs of pocket infection with a high risk of extrusion. Partial system extraction was performed, followed by 14 days of intravenous antibiotic therapy. Due to a history of ventricular fibrillation and permanent pacing dependency, and in the absence of viable transvenous access, a sequential implantation strategy was adopted using a leadless pacemaker (Micra AV, Medtronic) and a subcutaneous implantable cardioverter-defibrillator (EMBLEM, Boston Scientific). Both procedures were completed without complications, and the patient showed favorable recovery, with effective pacing, no arrhythmic recurrences, and no signs of infection at the six-month follow-up. This case illustrates the feasibility of a fully leadless approach in high-risk patients with contraindications to conventional transvenous systems.